More than two-thirds (68%) of the respondents to the survey expressed confidence that the COVID-19 is "behind us." An overwhelming majority (80%), though, indicated that annual COVID-19 vaccination will be needed for the foreseeable future.
Most every measure of the COVID-19 pandemic is trending downward, according to the Centers for Disease Control and Prevention (CDC). The CDC tracker this morning shows 1,052 deaths on weekly basis and an average of 1,511 daily hospitalization admissions.
Although the 2023 Annual Managed Healthcare Executive Pharmacy Survey was conducted Feb. 14-28, just over two-thirds (68%) of the approximately 300 respondents indicated then they were confident or very confident that the COVID-19 “was behind us.” Just 9% indicated that they were not confident that was not so.
Whether the methods used to count COVID-19 deaths are undercounting or overcounting the deaths from the disease has become an active controversy. In her column in the Washington Post, Leana Wen, M.D., M.Sc., a professor George Washington’s Milken Institute School of Public Health has argued that deaths being overcounted. Others have argued that the problem is undercounting.
Respondents to the Pharmacy Survey were solidly in the overcounting camp, with two-thirds (67%) indicated that they believed that deaths from COVID-19 were being overcounted. Nonetheless, a large majority (80%) said they believe annual COVID-19 vaccines will be needed for the foreseeable future.
The respondents were spread fairly evenly across the various sectors of the U.S. healthcare industry, with 20% self-identifying as working for hospitals, 22% for physician practices, 19% for pharmacy benefit managers, 16% for payer organizations, 13% for drug and device manufacturers and the rest in a variety of sectors.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
ICI-Chemo Combo Delivers More Benefit Than Harm, Even for High-Risk NSCLC Patients, Study Finds
May 16th 2025Immune checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), have been a huge advance in the treatment of non-small cell lung cancer. But it is open question whether they should be combined with traditional chemotherapy.
Read More